News & Alerts
-
Dec- 2023 -22 December
FDA Approves Safety Labeling Changes for Opioid Pain Medicines
The Food and Drug Administration (FDA) has officially granted final approval and implemented mandatory safety labeling updates for opioid analgesic…
Read More » -
22 December
Jazz Pharmaceuticals Faces Setback as PTSD Drug Fails Mid-Stage Trial
Jazz Pharmaceuticals (JAZZ.O) encountered a setback as its investigational drug, JZP150, designed for the treatment of post-traumatic stress disorder (PTSD),…
Read More » -
22 December
Bristol Myers Acquire Karuna Therapeutics in $14 Billion Megadeal
In a strategic move, Bristol Myers Squibb has announced a groundbreaking acquisition of Karuna Therapeutics for a staggering $14 billion,…
Read More » -
22 December
India’s High-Stakes Probe into Alleged Bribery Scandal in Toxic Syrup Tests Reaches Climax
In a significant development, India is reaching the final stages of its investigation into allegations that a state drug regulator…
Read More » -
22 December
Ono Pharmaceutical Collaborates with EVQLV for AI-Powered Antibody Development
Ono Pharmaceutical Co., Ltd., a prominent Japanese pharmaceutical company, has announced a strategic collaboration with EVQLV, INC, based in Miami,…
Read More » -
22 December
Ionis Pharmaceuticals’ WAINUA™ (Eplontersen) Secures FDA Approval for Hereditary Transthyretin-Mediated Amyloidosis Treatment
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has achieved a groundbreaking milestone with the U.S. Food and Drug Administration (FDA) granting approval…
Read More » -
22 December
Juniper Therapeutix Secures Exclusive Rights for Ensitrelvir, Groundbreaking COVID-19 Antiviral, from Ping An-Shionogi for Singapore
In a significant stride toward combating the evolving challenges of the COVID-19 pandemic, Juniper Therapeutix, a leading science-led healthcare company…
Read More » -
21 December
Philips North America LLC Recalls Panorama 1.0T HFO Due to Risk of Explosion
Philips North America LLC has issued a voluntary recall for its Panorama 1.0T HFO magnetic resonance (MR) system due to…
Read More » -
21 December
Nestle CEO, Mark Schneider, Downplays Impact of Weight-Loss Drugs on Coffee Sales
Nestle (NESN.S) Chief Executive, Mark Schneider, expressed confidence that the increasing popularity of weight-loss drugs, such as Eli Lilly’s (LLY.N)…
Read More » -
21 December
Switzerland Contemplates Unprecedented Move: Pilot Scheme for Recreational Cocaine Sales
Switzerland’s capital, Bern, is exploring a groundbreaking pilot scheme that would permit the recreational sale of cocaine, challenging traditional approaches…
Read More »